Published June 1985 by Elsevier Science & Technology .
Written in EnglishRead online
|Contributions||P. Von Wichert (Editor)|
|The Physical Object|
|Number of Pages||182|
Download Sustained Release Theophylline and Nocturnal Asthma
Twice daily sustained release theophylline gave satisfactory steady serum theophylline concentrations in asthmatic children aged 7 to 14 years. The children showed improvement in symptoms, less frequent waking at night, reduced use of beta agonist inhalers, and improved early morning peak flows while being treated with this by: Full text Full text is available as a scanned copy of the original print version.
Get a printable copy (PDF file) of the complete article (K), or click on a page image below to browse page by : H Davies, P Helms, J Stroobant. As theophyllines are stimulants of the central nervous system the effect of 10 days' twice daily treatment with sustained release choline theophyllinate or placebo on symptoms, overnight bronchoconstriction, nocturnal oxygen saturation, and quality of sleep were studied in a double blind crossover study in nine stable patients with nocturnal asthma Cited by: Sustained release theophylline and nocturnal asthma: international workshop, Bürgenstock, Switzerland.
" Sustained Release Theophylline: A Biopharmaceutical Challenge to a Clinical Need, Sustained Release Theophylline: In the Treatment of Crao, Sustained Release Theophylline: And Nocturnal Asthma." American Review of Author: Richard J.
Martin. Nocturnal wheeze is common in patients with asthma, and slow release theophyllines may reduce symptoms.
As theophyllines are stimulants of the central nervous system the effect of 10 days' twice daily treatment with sustained release choline theophyllinate or placebo on symptoms, overnight bronchoconstriction, nocturnal oxygen saturation, and Cited by: Many asthmatics complain of increased symptoms, awakenings, and need for additional medications during the sleeping hours.
Sustained-release theophylline (THEO) may be superior to conventional inhaled bronchodilators in preventing nocturnal asthma symptoms and the early morning decrement in lung function common to this population.
However, recent Cited by: Results: Sustained-release theophylline preparations are effective in decreasing the rate Sustained Release Theophylline and Nocturnal Asthma book exacerbations of nocturnal asthma symptoms, but theophylline has risks of major toxicity and serum concentrations must be monitored.
Inhaled corticosteroids are also useful in controlling nocturnal asthma, and they reduce inflammation, which is the basic Cited by: 3. Summary. The efficacy and side-effects of individually adjusted doses of controlled-release theophylline given once daily in the evening (average dose mg) were compared with those of standard treatment with controlled-release terbutaline mg b.d.
Thirty-six asthmatics with regular morning obstruction (“morning dipping”) were studied over two treatment periods each Cited by: 5. Available therapy includes inhaled and oral corticosteroids, sustained-release theophylline, long-acting b-agonists, leukotriene- modifying agents and anticholinergic medication.
The definition, epidemiology, potential mechanisms and management of nocturnal asthma are discussed in this by: Consumer information about the medication THEOPHYLLINE SUSTAINED-RELEASE - ORAL (Uniphyl), includes side effects, Sustained Release Theophylline and Nocturnal Asthma book interactions, recommended dosages, and storage information.
Read more about the prescription drug THEOPHYLLINE SUSTAINED-RELEASE - ORAL. Twice daily sustained release theophylline gave satisfactory steady serum theophylline concentrations in asthmatic children aged 7 to 14 years. The children showed improvement in symptoms, less frequent waking at night, reduced use of beta agonist inhalers, and improved early morning peak flows while being treated with this preparation.
There was Cited by: A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma.
Pediatrics ; Sherman J, Hutson A, Baumstein S, Hendeles L. Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions. This double-blind, placebo-controlled, cross-over trial was designed to evaluate the effectiveness of a twice-daily Bioavail slow-release theophylline capsule in a group of out-patient asthmatics, with a history of nocturnal and/or early morning wheeze or chest by: 1.
Theophylline (thee of' i lin) is an effective bronchodilator and is widely used in treatment of acute attacks of asthma and in chronic management of bronchospasm in patients with asthma and chronic obstructive pulmonary disease. Twice daily sustained release theophylline gave satisfactory steady serum theophylline concentrations in asthmatic children aged 7 to 14 years.
The children showed improvement in symptoms, less frequent waking at night, reduced use of beta agonist inhalers, and improved early morning peak flows while being treated with this preparation.
Comparison of Morning and Evening Dosing with a Hour Sustained-Release Theophylline, Uniphyl, for Nocturnal Asthma WILLIAM W. BUSSE, M.D. Sixteen adults who had chronic asthma with nocturnal symptoms ROBERT K. BUSH, M.D. were selected to evaluate and compare the effectiveness of 7 A.M.
Madison, Wisconsin versus 7 P.m. single daily dosing with the hour sustained-release Cited by: Nocturnal wheeze is common in patients with asthma, and slow release theophyllines may reduce symptoms.
As theophyllines are stimulants of the central nervous system the effect of 10 days' twice daily treatment with sustained release choline theophyllinate or placebo on symptoms, overnight bronchoconstriction, nocturnal oxygen saturation, and.
Nocturnal asthma: Understanding chronobiology and chronotherapy sustained-release theophylline. Fur. Chronotherapy of nocturnal asthma has shown promising results but right dosing and Author: Richard J Martin. Two different sustained-release theophylline preparations were used to determine (1) if the serum theophylline concentrations (STC) depend on the type and dosing schedule of the preparation, (2) the relationship between STC and the circadian variations in asthma, and (3) the effect of STC on sleep quality and respiratory patterns during the by: Nocturnal asthma: Mechanisms and management sustained-release theophylline, long-acting b-agonists, leukotriene- modifying agents and anticholinergic medication.
In conclusion, sustained. In a recently published study, Selby and colleagues 23 compared salmeterol, 50 μg taken twice daily, with individually titrated doses of extended-release theophylline, taken twice daily, in patients with nocturnal asthma.
In that study, few significant differences between salmeterol and theophylline were seen in pulmonary function, symptoms, adverse effects, polysomnography measurements, or patient perception of sleep Cited by: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child HealthAuthor: H Davies, P Helms, J Stroobant.
Makino S, Adachi M, Ohta K, et al; Safety of Sustained-Release Theophylline and Injectable Methylxanthines Committee; Asthma Prevention and Management Guidelines Committee.
A prospective survey on safety of sustained-release theophylline in treatment of asthma and COPD. Allergol Int. ; To examine the effects of once-daily, sustained-release theophylline on sleep patterns in nocturnal asthmatics.
Double-blind, randomised, cross-over, placebocontrolled trial over 22 days. Mostly sustained release formulation is used to manage the nocturnal asthma, because the half-life of β 2 sympathomometic agent is short (Not more than 7 hrs). In a prospective study, patients with asthma treated with theophylline were more likely to complain of sleep maintenance difficulty (55%) than were patients treated with other asthma medications (31%), and in a retrospective study of treated patients with asthma, 46% of.
Comparison of Once-Daily Evening Versus Morning Sustained-Release Theophylline Dosing For Nocturnal Asthma. Chronobiology International: Vol.
4, No. 3, pp. Cited by: Nocturnal cough and wheeze are common in asthma and often treated with beta2 agonists or theophyllines. As nocturnal asthma and these therapies may affect sleep and cognition, we compared 50 microg salmeterol inhaled every 12 h with individually dose-titrated sustained-release oral theophylline on sleep quality and cognitive performance in 15 patients with stable nocturnal asthma Cited by: Theophylline, also known as 1,3-dimethylxanthine, is a methylxanthine drug used in therapy for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma under a variety of brand names.
As a member of the xanthine family, it bears structural and pharmacological similarity to theobromine and caffeine, and is readily found in nature, being Metabolism: Hepatic to 1-methyluric acid.
The nocturnal worsening of asthma is a common phenonlcnon that renlains a therapeutic chal lenge. A eOlnnlonly used approach has been the evening use ofsustained-release theophylline.:l-5 This reginlen results in Inaxitnal theophylline concentra tions during the nocturnal period of increased bron.
A model of multi-unit dose tablets of theophylline (dose, mg) has been designed to give a prompt release dose ( mg) in the first 1 h and the remaining sustained release.
In a double-blind cross-over study, the effects of slow release (S-R) terbutaline tablets (b.i.d. mg/kg per day) and S-R theophylline ( mg/kg morning and mg/kg evening) were compared in eleven patients with nocturnal asthma. On day seven of each treatment period, drug serum concentrations and peak expiratory flow (PEF) were measured Cited by: Treatment with sustained-release theophylline has resulted in less total sleep time and time spent in slow-wave sleep than has treatment with placebo.
31 x 31 Rhind, GB, Connaughton, JJ, McFie, J et al. Sustained release choline theophylline in nocturnal asthma Cited by: Theophylline immediate-release pills are available in milligram (mg), mg, mg, mg, mg, and mg formulations.
Sustained release theophylline in nocturnal asthma. Arch Dis Child. ;59 Ora, J. et al. Efficacy and safety profile of doxofylline compared to theophylline in asthma. Theophylline, Sustained release Tablets and Capsules. Multiple products: Uniphyl As well as generic versions.
Long-term control and prevention of symptoms, especially nocturnal symptoms. Any age. Variable in each individual based upon weight. Find out more about asthma. titrated doses of extended-release theophylline, taken twice daily, on nocturnal asthma control and sleep quality through objective and subjective mea-sures of efficacy.
Materials and Methods Patient Population Nonsmoking men and nonpregnant women who were $ 18 years of age and who had nocturnal asthma were selected for study participation.
Twenty school children with chronic asthma who despite regular prophylactic therapy continued to have trouble-some nocturnal wheeze or cough entered a double-blind cross-over study in which a once daily theophylline preparation was compared with placebo to assess control of these symptoms.
Seventeen children completed both phases of the by: Long-acting inhaled β2 agonists (e.g. salmeterol, formoterol) are effective in managing nocturnal asthma that is inadequately controlled by anti-inflammatory agents.
In addition, sustained release theophylline and controlled release oral β2 agonists are by: • Role in therapy–Sustained-release theophylline and aminophylline can be used as controller medications in asthma.
Many clinical studies have shown that long-term treatment with sustained-release theophylline is effective in controlling asthma symptoms and File Size: KB. In a placebo-controlled, double-blind cross-over study of 2 X 3 weeks' duration, twenty-four children with stable asthma who were wheezing during the night, were treated with a single dose of sustained-release theophylline (SRT) taken after supper.
The mean serum theophylline levels 4 and 12 hr after dosing were and mg/l, by: We wished to assess the efficacy of inhaled salmeterol (SML; 50 micrograms b.i.d.) compared to a combination of slow-release theophylline and ketotifen p.o. (TK; T mg+K 1 mg b.i.d.) for the treatment of nocturnal asthma.
Ninety six patients with nocturnal asthma, (forced expiratory volume in one second (FEV1) % of predicted value, reversibility > or = 15%, at least two nocturnal.In an effort to isolate the effect of theophylline on sleep from the effect of asthma, we examined the impact of oral theophylline on sleep quality in normal, nonasthmatic subjects.
Ten healthy, nonsmoking, male subjects ranging in age from 23 to 35 were studied. The subjects were randomly divided into two groups and studied in a double-blinded, crossover designed by: